Abstr# 2612: Minocycline as an option for refractory calcinosis in scleroderma. 43% of patients reported some improvement. With few options available, this would be something to consider. #ACR19 @rheumnow https://t.co/yXvmUwaxzU

We know ovarian insuff with cyclophosphamide is dose-related, but in SLE data from @EmoryUniversity @emoryhealthcare the absolute numerical diff between success & failure is tighter than I imagined. Other factors at play? Also: time heals some wounds... #ACR19 ABST2293 @RheumNow https://t.co/wI3S4ljjOJ

Dr. Suzanne Li discusses juvenile localized scleroderma disease activity at #ACR19: jLS can cause severe damage. There is no universal activity feature for jLS so need to assess multiple features, such as -Erythema -Violaceous color -Waxy white/yellow #pedsrheum @RheumNow https://t.co/BpszRgHhyr

Ixekizumab in nrAXSpa Outcomes met. Another positive trial #ACR19 @rheumnow Abst2729 https://t.co/VVUKSi6sCQ

Ixekizumab in nrAXSpa: COAST-X switch at wk16 for 52wk study IXE 2wkly vs 4wkly vs PBO 303pts #ACR19 @rheumnow Abst2729

@KDAO2011 teaching us about SLE @RheumNow #ACR19 it’s almost your last chance to swing by the rheumnow booth! https://t.co/pBdFAwGXtm

Dr Atul Deodhar wows the crowd at #ACR19 showing abtract #2729 Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Phase 3 Trial showing IXE is effective by ASAS40. https://t.co/Bcb20FYNoH

How should VECTRA be used, if at all? -Bathon I don't use VECTRA routinely, it's as good as your physical exam. -Bykerk: I've yet to find a good reason to use it. -Emery ::no comment:: -Mikuls: I don't think there's a place in my clinic to use it. #ACR19 @RheumNow

@cappelliMD @Richter_MD @LCalabreseDO @CCalabreseDO @lexmeara @UmaThanaMD Nice work @Richter_MD - such an important phenomenon. It’s always something nice to tell my melanoma irAE patients: your arthritis might be nasty, but at least there’s a substantive upside! #ACR19 ABST2137 @RheumNow (sorry to miss you in person!) https://t.co/x1T9n9eekG

38yo F with seroneg RA on 3x therapy with synovitis. What tx do you choose? -Bathon: Confirm dx, use biologic, avoid ritux -Bykerk: Ask about JIA, use TNF, JAK, IL-6 -Emery: Not ritux. Use steroids, consider TNFi, urgent tx is not needed -Mikuls: Agree with above #ACR19 @RheumNow

@RheumNow Should note this was not the first JAKi in this space; similar trial using tofacitinib in 2017 https://t.co/NrEul0wLp9

#ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores. Good safety profile but too small a trial to assess properly Overall an encouraging result, JAKi impacting yet another disease! @RheumNow https://t.co/GtB9wHuoNp

Upadacitinib in AS Nice to the rapid response #ACR19 @rheumnow Abst2728 https://t.co/woAZbdb5QY

What's your option for RA patients with MTX failure? -Bathon: Triple therapy vs. biologic (etanercept or adalimumab) -Bykerk: Maximize MTX to 25mg SQ -Emery: Adalimumab is our cheapest and most effective therapy -Mikuls: Usually TNFi, typically etanercept #ACR19 @RheumNow

Do you hold MTX in men who want to conceive? #ACR19 @RheumNow